The European Union's healthcare landscape is on the verge of a significant transformation with the impending implementation of the new Health Technology Assessment (HTA) regulation. Set to take effect in 2025, this regulation aims to harmonize the clinical assessment process across EU member states, potentially streamlining market access for new drugs and medical devices. However, it also introduces new challenges for drug developers who must adapt their strategies to navigate this evolving regulatory environment effectively.
This summary is based on the webinar held on the 10th of October 2024 by industry experts Chantal van Gils and Maxwell Craig, the second installment of our webinar series Navigating the New EU HTA Regulation with Confidence.
Watch the recording below, or download the PDF summary for key steps and takeaways.
